The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma

Annals of Hematology

Volumn 93, Issue 7, 2014, Pages 1207-1214

  Rasche, Leo ^a   Strifler, Susanne ^a   Duell, Johannes ^a   Rosenwald, Andreas ^b   Buck, Andreas ^a   Maeder, Uwe ^a   Einsele, Hermann ^a   Knop, Stefan ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Dexa BEAM; Extramedullary multiple myeloma; High risk myeloma; Ki67; Polychemotherapy; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN;

ADULT; ADVANCED CANCER; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEAM THERAPY; BLOOD TOXICITY; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INFECTIOUS COMPLICATION; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84902659274     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2023-2     Document Type: Article

References (37)

1. Rasche L, Bernard C, Topp MS, Kapp M, Duell J, Wesemeier C, Haralambieva E, Maeder U, Einsele H, Knop S (2012) Features of extramedullarymyeloma relapse: high proliferation,minimalmarrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol 91(7):1031-1037. doi:10.1007/s00277-012-1414-5
2. Sheth N, Yeung J, Chang H (2009) p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res 33(10):1357-1360. doi:10.1016/j.leukres.2009.01.010
3. Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T (2002) Proliferation, apoptosis, and intratumoural vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 55(7):530-534 (Pubitemid 34779306)
4. Minarik J, Scudla V, Ordeltova M, Pika T, Bacovsky J, SteinbachM, Kumar V, Van Ness B (2011) Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis. Leuk Res 35(1):44-48. doi:10.1016/j.leukres.2010.04.015
5. Ely S (2011) Renewed interest in myeloma tumor growth, or just one more method to assess proliferation? Leuk Res 35(1):30-31. doi:10.1016/j.leukres. 2010.07.029
6. Drexler HG, Matsuo Y (2000) Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res 24(8):681-703 (Pubitemid 30495502)
7. Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions.Nat Rev Cancer 2(3):175-187. doi:10.1038/nrc746 (Pubitemid 37328787)
8. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC (2007) The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin N Am 21(6):1007-1034. doi:10.1016/j.hoc.2007.08.007, vii-viii (Pubitemid 350051349)
9. Lopez-Anglada L, Gutierrez NC, Garcia JL, Mateos MV, Flores T, San Miguel JF (2010) P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol 84(4): 359-361. doi:10.1111/j.1600-0609. 2009.01399.x
10. Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kroger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann HH, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G (2013) Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. doi:10.1111/bjh.12223
11. Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol 23(26):6333-6338. doi:10.1200/JCO.2005.05.021 (Pubitemid 46218843)
12. Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D, Apperley JF (2005) Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 75(5):376-383. doi:10.1111/j.1600-0609.2005.00531.x (Pubitemid 41445076)
13. Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi CX, Schmidt J, Liang WS, Craig DW, Carpten JD, Stewart AK (2013) Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 161(5):748-751. doi:10.1111/bjh.12291
14. Billecke L, Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kroger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G (2012) Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma. Anticancer Res 32(5): 2031-2034
15. Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 98(2):360-364. doi:10.3324/haematol.2013.094409
16. Blade J, Fernandez de Larrea C, Rosinol L (2012) Extramedullary involvement in multiple myeloma. Haematologica 97(11):1618-1619. doi:10.3324/haematol.2012.078519
17. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol Off J Eur Soc Med Oncol ESMO 21(2):325-330. doi:10.1093/annonc/mdp329
18. Perez-Simon JA, Sureda A, Fernandez-Aviles F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomas JF, Moraleda JM, Alegre A, Canizo C, Brunet S, Rosinol L, Lahuerta J, Diez-Martin JL, Leon A, Garcia A, Vazquez L, Sierra J, San Miguel JF, Grupo Espanol de M (2006) Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leuk Off J Leuk Soc Am Leuk Res Fund UK 20(3):542-545. doi:10.1038/sj.leu.2404085
19. Usmani SZ, Heuck C,Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y,Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97(11):1761-1767. doi:10.3324/haematol.2012.065698
20. Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol Off J Am Soc Clin Oncol 29(28):3805-3812. doi:10.1200/JCO.2011.34.9290
21. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, GertzM, Kumar S, Mikhael J, Roy V, Kyle RA, LacyMQ (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund UK 25(6):906-908. doi:10.1038/leu.2011.29
22. Damaj G, Mohty M, Vey N, Dincan E, Bouabdallah R, Faucher C, Stoppa AM, Gastaut JA (2004) Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol 73(6):402-406. doi:10.1111/j.1600-0609.2004.00331.x (Pubitemid 39564362)
23. Moreau P, Polliack A (2013) Extramedullary multiple myeloma: extraosseous relapse is extra "bad news", but why? Leuk Lymphoma 54(7):1349-1350. doi:10.3109/10428194.2012.753451
24. Papanikolaou X, Repousis P, Tzenou T,Maltezas D, Kotsopoulou M, Megalakaki K, Angelopoulou M, Dimitrakoloulou E, Koulieris E, Bartzis V, Pangalis G, Panayotidis P, KyrtsonisMC (2013) Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma 54(7):1459-1464. doi:10.3109/ 10428194.2012.746683
25. Durie BG, Harousseau JL,Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working G (2006) International uniform response criteria for multiple myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund UK 20(9):1467-1473. doi:10.1038/sj.leu.2404284
26. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V,Marrow T, German Hodgkin's Lymphoma Study G, Lymphoma Working Party of the European Group for B (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359(9323):2065-2071. doi:10.1016/S0140- 6736(02)08938-9 (Pubitemid 34680969)
27. Munshi NC, Anderson KC (2013) New strategies in the treatment of multiple myeloma. Clin Cancer Res Off J AmAssoc Cancer Res. doi: 10.1158/1078-0432.CCR- 12-1881
28. Calvo-Villas JM, Alegre A, Calle C, Hernandez MT, Garcia-Sanchez R, Ramirez G, Gem-Pethema/Spanish Myeloma Group S (2011) Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol 87(3):281-284. doi:10.1111/j.1600-0609.2011.01644.x
29. Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M, Segarra M, Cid MC, Filella X, Montserrat E (2004) Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 89(7):832-836 (Pubitemid 38981343)
30. Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I (2001) Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 42(4):683-687. doi:10.3109/10428190109099330 (Pubitemid 32782776)
31. Rosinol L, CibeiraMT, Uriburu C, Yantorno S, Salamero O, Blade J, Montserrat E (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76(5): 405-408. doi:10.1111/j.0902-4441.2005. t01-1-EJH2462.x
32. Hallack Neto AE, Borges dos Santos K, Atalla A (2012) Modified BEAM conditioning regimen in patients with Hodgkin and non- Hodgkin lymphomas. Exp Clin Transplant Off J Middle East Soc Organ Transplant 10(6):622
33. Egan JB, Shi CX, TembeW, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK (2012) Wholegenome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120(5):1060-1066. doi:10.1182/blood-2012-01-405977
34. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, DispenzieriA,Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120(5):1067-1076. doi:10.1182/blood-2012-01-405985
35. Bahlis NJ (2012) Darwinian evolution and tiding clones in multiple myeloma. Blood 120(5):927-928. doi:10.1182/blood-2012-06-430645
36. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS (2013) Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. doi:10.1158/2159-8290.CD-13-0014
37. Stessman HA,Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B (2013) Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leuk Off J Leuk Soc Am Leuk Res Fund UK. doi:10.1038/leu.2013.148